Merck is dropping $9.2 billion on Cidara Therapeutics, primarily for CD388, a flu antiviral. That's a hefty price tag, even for a company of Merck's size. The question, as always,...
Can AI's Stock Downgrade of Alibaba Actually Be a Good Thing? Here's the thing about AI: it's not just about crunching numbers faster. It's about seeing patterns, identifying risks...
[Generated Title]: Netflix's Stock Split: Desperate Move or Genius Play? My Take. Alright, Netflix did a 10-for-1 stock split. Big deal. Shares were trading above $1,100, now they'...
Okay, folks, buckle up. I know the headlines are buzzing with words like "disconnect" and "growing pains" when it comes to Nvidia and their enterprise software. We're seeing report...
Title: Decoding Market Mood Swings: Beyond the VIX Hype The Cboe Volatility Index, or VIX, is often touted as the market's "fear gauge." It's plastered across financial news, cited...
Alright, let's get one thing straight: I'm so sick of hearing about Blue Origin's "stunning success." Rocket Report: Blue Origin’s stunning success; vive le Baguette One! Another b...
$35 Flights? Sounds Like a Trap to Me Okay, so Avelo Airlines is bragging about $35 flights from Concord. Thirty-five freakin' dollars. Yeah, right. Like anyone actually gets that...
Cidara's $9.2 Billion Buyout: Proof That Biotech's Boldest Bets Pay Off Big Okay, everyone, buckle up because this is exactly the kind of news that gets me absolutely buzzing about...
Doug McMillon's Exit: A Decade of Quadrupled Stock Prices and a Sustainability "Win" Six Years Early – But What's the Real ROI? Doug McMillon's upcoming retirement from Walmart, sl...
Zcash's Savior or Just Another Crypto Hype Train? Alright, let's get this straight. Leap Therapeutics – Leap Therapeutics? – is rebranding itself as "Cypherpunk Technologies Inc."...